108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
度普利尤单抗在中国未控制的重度哮喘患者中的成本效用分析
Authors Liu Z , Xu M, Zhu H, Huang J, Ye X, Shen X , Fan X
Received 6 June 2025
Accepted for publication 19 September 2025
Published 3 October 2025 Volume 2025:18 Pages 1355—1366
DOI https://doi.org/10.2147/JAA.S545324
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Amrita Dosanjh
Zheng Liu,1 Maosheng Xu,2 Huifang Zhu,1 Jinzhen Huang,1 Xuhui Ye,1 Xintian Shen,1 Xiaomei Fan1
1Department of Pharmacy, Shenzhen Baoan Women’s and Children’s Hospital, Shenzhen, 518102, People’s Republic of China; 2Department of Respiratory, Guangzhou Panyu District Maternal and Child Health Hospital, Guangzhou, 511400, People’s Republic of China
Correspondence: Xiaomei Fan, Department of Pharmacy, Shenzhen Baoan Women’s and Children’s Hospital, Shenzhen, 518102, People’s Republic of China, Email xmfane@163.com
Purpose: Dupilumab’s recent approval in China as an add-on therapy for asthma provides a novel therapeutic alternative for severe asthma management, but its economic benefits remain unsubstantiated in China. This study aimed to adopt a cost-utility analysis to evaluate the economics of dupilumab in the treatment of uncontrolled severe asthma and provide an evidence-based reference for clinical decision-making and therapeutic regimen selection.
Methods: From the healthcare perspective, a Markov model was developed to simulate costs and quality-adjusted life years (QALYs) over a five-year time horizon for uncontrolled severe asthma patients aged ≥ 12 years receiving either dupilumab add-on therapy or standard-of-care (SoC) therapy alone. The incremental cost-utility ratio (ICUR) served as the primary outcome and was compared with the willingness-to-pay (WTP) threshold based on per capita gross domestic product (GDP) of China ($13,444.68/QALY) to determine the economics of therapeutic alternatives. The robustness of the results was verified using sensitivity analysis, and the impact of the dupilumab price on outcomes was evaluated using scenario analysis.
Results: Compared with SoC therapy, dupilumab add-on therapy incurred higher costs but provided greater utility gains, with an ICUR of $83,941.87 per QALY gained, which exceeded the WTP threshold. One-way sensitivity analysis identified the utility of controlled asthma as the predominant influential factor, followed by the price of dupilumab. Probabilistic sensitivity analysis showed that 98.8% of simulations were consistent with the base-case results, and SoC therapy had a higher probability of cost-utility acceptability than dupilumab add-on therapy. Scenario analysis revealed that reducing dupilumab’s price to $70.38 would render its ICUR below the WTP threshold.
Conclusion: Based on the current Chinese healthcare system, it was not cost-utility to apply dupilumab as an add-on therapy for patients aged ≥ 12 years with uncontrolled severe asthma. A substantial price reduction of dupilumab could improve affordability in this patient population.
Keywords: dupilumab, biologics, severe asthma, pharmacoeconomics, cost-utility analysis
1Department of Pharmacy, Shenzhen Baoan Women’s and Children’s Hospital, Shenzhen, 518102, People’s Republic of China; 2Department of Respiratory, Guangzhou Panyu District Maternal and Child Health Hospital, Guangzhou, 511400, People’s Republic of China
Correspondence: Xiaomei Fan, Department of Pharmacy, Shenzhen Baoan Women’s and Children’s Hospital, Shenzhen, 518102, People’s Republic of China, Email xmfane@163.com
Purpose: Dupilumab’s recent approval in China as an add-on therapy for asthma provides a novel therapeutic alternative for severe asthma management, but its economic benefits remain unsubstantiated in China. This study aimed to adopt a cost-utility analysis to evaluate the economics of dupilumab in the treatment of uncontrolled severe asthma and provide an evidence-based reference for clinical decision-making and therapeutic regimen selection.
Methods: From the healthcare perspective, a Markov model was developed to simulate costs and quality-adjusted life years (QALYs) over a five-year time horizon for uncontrolled severe asthma patients aged ≥ 12 years receiving either dupilumab add-on therapy or standard-of-care (SoC) therapy alone. The incremental cost-utility ratio (ICUR) served as the primary outcome and was compared with the willingness-to-pay (WTP) threshold based on per capita gross domestic product (GDP) of China ($13,444.68/QALY) to determine the economics of therapeutic alternatives. The robustness of the results was verified using sensitivity analysis, and the impact of the dupilumab price on outcomes was evaluated using scenario analysis.
Results: Compared with SoC therapy, dupilumab add-on therapy incurred higher costs but provided greater utility gains, with an ICUR of $83,941.87 per QALY gained, which exceeded the WTP threshold. One-way sensitivity analysis identified the utility of controlled asthma as the predominant influential factor, followed by the price of dupilumab. Probabilistic sensitivity analysis showed that 98.8% of simulations were consistent with the base-case results, and SoC therapy had a higher probability of cost-utility acceptability than dupilumab add-on therapy. Scenario analysis revealed that reducing dupilumab’s price to $70.38 would render its ICUR below the WTP threshold.
Conclusion: Based on the current Chinese healthcare system, it was not cost-utility to apply dupilumab as an add-on therapy for patients aged ≥ 12 years with uncontrolled severe asthma. A substantial price reduction of dupilumab could improve affordability in this patient population.
Keywords: dupilumab, biologics, severe asthma, pharmacoeconomics, cost-utility analysis